Conformational Response to Ligand Binding in Phosphomannomutase2

INSIGHTS INTO INBORN GLYCOSYLATION DISORDER*§

Received for publication, June 4, 2014, and in revised form, October 14, 2014. Published, JBC Papers in Press, October 16, 2014, DOI 10.1074/jbc.M114.586362

Giuseppina Andreotti†1, Israel Cabeza de Vaca§1, Angelita Pozziello†§¶, Maria Chiara Monti†, Victor Guallar§1¶10, and Maria Vittoria Cubellis‡1

From the †Istituto di Chimica Biomolecolare-Consiglio Nazionale Delle Ricerche, 80078 Pozzuoli, Italy, §Joint Barcelona Supercomputing Center-Genevac Regulation-Institute for Research in Biomedicine Research Program in Computational Biology, Barcelona Supercomputing Center, c/Jordi Girona 29, 08034 Barcelona, Spain, ¶Dipartimento di Farmacia, Università degli Studi di Salerno, 84084 Fisciano, Italy, **Institució Catalana de Recerca i Estudis Avançats, Passeig Lluís Companys 23, 08010 Barcelona, Spain, and ¶¶Dipartimento di Biologia, Università Federico II, 80126 Naples, Italy

Background: Mutations in phosphomannomutase2 cause glycosylation disorder, a disease without a cure that will largely benefit from accurate ligand-bound models.

Results: We obtained two models of phosphomannomutase2 bound to glucose 1,6-bisphosphate and validated them with limited proteolysis.

Conclusion: Ligand binding induces a large conformational transition in PMM2.

Significance: We produce and validate closed-form models of PMM2 that represent a starting point for rational drug discovery.

The most common glycosylation disorder is caused by mutations in the gene encoding phosphomannomutase2, producing a disease still without a cure. Phosphomannomutase2, a homodimer in which each chain is composed of two domains, requires a bisphosphate sugar (either mannose or glucose) as activator, opening a possible drug design path for therapeutic purposes. The crystal structure of human phosphomannomutase2, however, lacks bound substrate and a key active site loop. To speed up drug discovery, we present here the first structural model of a bisphosphate substrate bound to human phosphomannomutase2. Taking advantage of recent developments in all-atom simulation techniques in combination with limited and site-directed proteolysis, we demonstrated that α-glucose 1,6-bisphosphate can adopt two low energy orientations as required for catalysis. Upon ligand binding, the two domains come close, making the protein more compact, in analogy to the enzyme in the crystals from Leishmania mexicana. Moreover, proteolysis was also carried out on two common mutants, R141H and F191L. It was an unexpected finding that the mutant most frequently found in patients, R141H, although inactive, does bind α-glucose 1,6-bisphosphate and changes conformation.

Defects in human phosphomannomutase2 (PMM2)4 are the cause of an autosomal recessive glycosylation disorder, PMM2-CDG (OMIM entry 212065), also known as CDG1A or Jaeken syndrome. PMM2-CDG is characterized by underglycosylated glycoproteins and is associated with severe mental and psychomotor retardation (1). More than 85 missense mutations have been described for the gene encoding PMM2 (2), the most common involving an arginine in position 141, R141H (rs28936415; NM_000303.2: c.422G>A; NP_000294.1: p.R141H) with a frequency of 8 of 1000 in a default global population (1000 genome phase 1 genotype data from 1094 worldwide individuals), and 1 of 60/80 in Northern Europe populations (3). This mutation, which abolishes activity, has never been observed in homozygosity probably because complete lack of phosphomannomutase2 activity is lethal (4, 5). Often, patients are compound heterozygotes with at least one hypomorphic mutation (6). The second most frequent mutation, F119L (rs80338701; NM_000303.2: c.357C>T; NP_000294.1: p.F119L), which occurs at the interface between subunits and retains activity, has been observed in association with R141H but also in homozygous patients (5).

No pathologies have been associated yet to a paralogous enzyme, phosphomannomutase1 (PMM1), also present in humans (7). Both enzymes catalyze the reversible conversion of mannose 6-phosphate into mannose 1-phosphate or, to a smaller extent, the conversion of glucose 6-phosphate into glucose 1-phosphate (Glc-1-P), requiring activation by α-glucose 1,6-bisphosphate (Glc-1,6-P2) or α-mannose 1,6-bisphosphate (8). Twenty-one sequences and five crystal structures of phosphomannomutase from Eukaryota are known; the apo x-ray structure of PMM2 (Protein Data Bank code 2AMY) was solved

* This work was supported by Telethon-Italy Grant GGP12108 and European Research Council Grant ERC-2009-Adg 25027-PELE.

† To whom correspondence may be addressed: LifeScience Dept., Barcelona Supercomputing Center, c/Jordi Girona 29, 08034 Barcelona, Spain. Tel: 34-934137727; Fax: 34-934137721; E-mail: victor.guallar@bsc.es.

‡ To whom correspondence may be addressed: Dipartimento di Biologia, Complesso di Monte Sant’Angelo, Via Cinthia, Naples 80126, Italy. Tel: 39-081-679-118; Fax: 39-081-679233; E-mail: cubellis@unina.it.

§ The abbreviations used are: PMM, phosphomannomutase; PELE, Protein Energy Landscape Exploration; Glc-1,6-P2, α-glucose 1,6-bisphosphate; Glc-1-P, glucose 1-phosphate; CDG, congenital disorder of glycosylation; RP, reverse phase; r.m.s.d., root mean square deviation; DHCH, 1,2-cyclohexanediol; PMM_LEIME, phosphomannomutase from L. mexicana.
as were those of PMM1 in the absence of sugar ligand (Protein Data Bank code 2FUC) and in the presence of mannose 1-phosphate (Protein Data Bank code 2FUE) (9). Phosphomannomutase from *Leishmania mexicana* (PMM_LEIME) (10) has been crystallized in the absence of sugar ligand (Protein Data Bank code 2I54) and in the presence of β-glucose 1,6-bisphosphate (Protein Data Bank code 2I55), and in this last case, the protein is seen in closed conformation. Moreover, only one chain is found in the asymmetric unit of 2AMY, 2FUE, and 2FUC, whereas 2I54 and 2I55 contain dimers; an equilibrium exists for PMM2 that is shifted toward the dimer in the wild type and toward the monomer in F119L (11).

Although many therapeutic strategies are being evaluated for PMM2-CDG (12–15), there is still no cure for this disease. Among others, enhancement of activators such as Glc-1,6-P2 above the normal concentration has been proposed (11). The screening for suitable drugs is time- and money-consuming but can certainly speed up rational design based on accurate structural protein-ligand knowledge. Regrettably, only the structure of the apoenzyme in the open conformation is available for PMM2. The comparison of PMM_LEIME structures 2I54 and 2I55 shows that it undergoes induced fit and a large domain rearrangement upon ligand binding. We hypothesize that a similar change occurs in PMM2. For this reason, before attempting structure-based virtual screening, a suitable model of the receptor enzyme in closed form has to be built.

In this study, our hypothesis was analyzed by combining experimental and computational techniques. All-atom computational modeling has experienced a remarkable step forward with recent developments in software and hardware. Accurate non-biased ligand migration and binding associated to microsecond time scale protein dynamics are readily obtained now by means of molecular dynamics (16) or Monte Carlo techniques (17). Using the Protein Energy Landscape Exploration (PELE) software (17, 18) based on a combination of a Monte Carlo technique with protein structure prediction algorithms, we demonstrate that PMM2 undergoes a large conformational change upon ligand binding that is similar to PMME_LEIME. Moreover, we produced two enzyme models in the presence of 0.5 mM Glc-1,6-P2 representing two alternative binding modes. To support the models, we carried out limited proteolysis on wild type PMM2 as well as on two common mutants, F119L and R141H. The latter inactive mutant binds the ligand and undergoes a conformational change, making it more resistant to proteases and thermal unfolding.

**EXPERIMENTAL PROCEDURES**

DEAE-Sephrose Fast Flow, Superdex 75, and thrombin were purchased from GE Healthcare. Phosphoglucose isomerase from rabbit muscle, phosphomannose isomerase from *Escherichia coli*, glucose-6-phosphate dehydrogenase from *bakers’ yeast* (*Saccharomyces cerevisiae*), α-d-glucose 1,6-bisphosphate potassium salt hydrate, α-d-glucose 1-phosphate disodium salt hydrate, and β-nicotinamide adenine dinucleotide phosphate sodium salt were purchased from Sigma-Aldrich. SYPRO Orange was from Invitrogen Molecular Probes. Sodium orthovanadate was from Acros Organics. All other reagents were of analytical grade.

**Protein Expression and Purification**—Wild type, F119L, and R141H were expressed in *E. coli* BL21(DE3) strain grown at 37 °C in LB broth containing 0.2 mg/ml ampicillin. The expression and purification of wild type (WT) were performed as described (8) with only minor changes. The expression and purification of F119L were performed as described previously (11). The expression of R141H was assessed. The best production of the protein was obtained by adding 0.4 mM isopropyl 1-thio-β-d-galactopyranoside when the optical density was 1.0 and prolonging the incubation for 4 h after induction. The cells were then harvested, washed with PBS, and enzymatically lyzed (in 50 mM Hepes, pH 7.5 containing 1 mM 2-mercaptoethanol, 150 mM NaCl, 5 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride), and ammonium sulfate was added to the clear homogenate up to 60% saturation. The precipitate was recovered, redissolved in buffer, dialyzed against 50 mM Hepes, pH 7.1 containing 1 mM 2-mercaptoethanol and loaded onto a DEAE-Sephrose Fast Flow column equilibrated with the same buffer. The pass-through was collected, concentrated by ultrafiltration, and fractionated on a Superdex 75 column equilibrated with 20 mM Hepes, 1 mM MgCl2, 150 mM NaCl, pH 7.5.

**Enzyme Assay**—The enzymatic activity was routinely measured at 32 °C in 20 mM Hepes, pH 7.5 containing 1 mM MgCl2, 150 mM NaCl, 0.25 mM NADP+, 0.1 mg/ml BSA in the presence of 0.6 mM Glc-1-P, 0.08 mM Glc-1,6-P2, 0.01 mg/ml glucose-6-phosphate dehydrogenase, 0.01 mg/ml phosphoglucomutase isomerase, and 0.0032 mg/ml phosphomannose isomerase. The activity was followed spectrophotometrically at 340 nm, and the reduction of NADP+ to NADPH was recorded. When the effect of calcium ions was tested, the enzymatic activity was measured as described above in the presence of calcium chloride ranging from 0 to 400 μM.

**Limited Proteolysis**—Purified WT, F119L, and R141H were incubated (0.4 mg/ml) with thrombin (500 milliunits/μg of protein) in 20 mM Hepes, pH 7.5, 150 mM NaCl, 1 mM MgCl2, at 37 °C. The experiment was contemporarily performed in the presence of 0.5 mM Glc-1,6-P2. Aliquots were withdrawn, and residual phosphoglucomutase activity was assayed (except for R141H) over a period of 2 h. Additional aliquots were withdrawn and treated with acetic acid (10% final concentration) for reverse phase liquid chromatography-mass spectrometry (RP-LC-MS) analysis.

**RP-LC-MS analyses** were carried out on a Q-ToF-Premiere (Waters) equipped with an Alliance binary pump using a Jupiter C4 column (5 μm, 300 Å, 50 mm; Phenomenex). The chromatographic runs were carried out using H2O, 0.1% trifluoroacetic (buffer A) and acetonitrile, 0.1% trifluoroacetic (buffer B) from 10 to 80% buffer B in 30 min. All mass spectra were acquired from 500 to 2500 m/z values. Horse heart myoglobin was used for tuning the Q-ToF-Premiere instrument and for mass calibration. All data were acquired and analyzed by Mass Lynx 4.0, and peptide identifications were carried out with the assistance of Paws software.

Purified WT-PMM2, F119L, and R141H (1.5 μM) were incubated with 1,2-cyclohexanediene (molar excess of 100) in 100 mM sodium borate, pH 8.5 at 37 °C. The experiment was carried out with or without 0.5 mM Glc-1,6-P2. Aliquots were withdrawn after 20, 80, 140, and 200 min of reaction and injected.
onto an RP-LC-electrospray ionization-MS system. RP-LC-electrospray ionization-MS analyses were carried out as described above. Then, all samples were purified by Microcon filters (EMD Millipore) with a 10-kDa cutoff and incubated with trypsin (enzyme:protein ratio, 1:20 (w/w)) for 90 min at 37 °C. Each sample was loaded on a MALDI plate using 4-hydroxycinnamic acid as matrix, and the peptide fingerprint was recorded on a MALDI-Micro (Waters) using enolase mixture as calibrant.

The WT enzyme was also incubated (1.4 mg/ml) at 37 °C with trypsin (protease:enzyme ratio, 1:20) under the same conditions in the presence of 0.5 mM Glc-1,6-P₂, 0.5 mM Glc-1-P, or 0.5 mM Glc-1-P plus 0.5 mM vanadate (a PMM2 inhibitor that mimics phosphate). Residual phosphoglucomutase activity was assayed over a period of 4 h.

**Thermal Stability**—Heat-induced melting profiles of WT, F119L, and R141H were recorded by thermal shift assay using an iCycler iQ Real Time PCR Detection System (Bio-Rad). The proteins (0.275 mg/ml) were equilibrated in 20 mM Hepes, pH 7.5, 2 mM MgCl₂, 150 mM NaCl, 1 mM dithiothreitol, 2.4 mM SYPRO Orange and distributed in 96-well PCR plates, and appropriate ligand solutions (in water) were added (the final volume was 0.025 ml in each well). The plates were sealed with optical quality sealing tape and heated from 25 to 80 °C at 0.5 °C/min. The excitation wavelength was 490 nm, and the emission wavelength was 575 nm. The experiment was performed in the presence of no ligand, 5 mM EDTA, 0.5 mM Glc-1-P, 0.5 mM Glc-1-P plus 0.5 mM vanadate, 0.5 mM vanadate, and 0.5 mM Glc-1,6-P₂.

**Miscellaneous Method**—The Bradford colorimetric assay was used for protein quantification (19) using the Bio-Rad Protein Assay with bovine serum albumin as standard.

**Atomic Model Preparation**—The Protein Data Bank 2AMY structure had some problems that needed to be fixed before running PELE. The most important aspect was the lack of two Mg²⁺ ions and this loop by superposition to the PMM1 structure, 2FUC. Importantly, PMM1 has the same loop length and the 207–222 loop region. We added the Mg²⁺ ions and those...
tation is quite different from that found in homologous enzymes. The corresponding loops in PMM1 or PMM_LEIME are well ordered and bind Mg$^{2+}$. Due to the disorder of this loop in 2AMY, Asp$^{217}$ is quite far from the other two residues, Asp$^{12}$ and Asp$^{14}$, that form an acidic triad that binds Mg$^{2+}$ and contributes to catalysis (Asp$^{19}$, Asp$^{21}$, and Asp$^{226}$ in PMM1 and Asp$^{10}$, Asp$^{12}$, and Asp$^{215}$ in PMM_LEIME). For this reason, we generated a native-like initial model grafting the backbone of the loop and the Mg$^{2+}$ ion from PMM1, predicting the side-chain conformations, and minimizing the resulting model (see “Experimental Procedures” for more details and supplemental Structure 1). Additionally, a reference bound complex was obtained by superposition of our initial model to the holo-PMM_LEIME (Protein Data Bank code 2I55) and by copying the glucose 1,6-bisphosphate ligand into our initial PMM2 model. Such a reference compound allowed us to qualitatively assess the ligand evolution along the free migration performed in PELE (17, 18).

Fig. 1A shows the protein-ligand interaction energy against the ligand r.m.s.d. to the bound reference complex along the PELE 200-independent trajectory global search. As mentioned, the bound reference structure serves only as an indication of the active site area and not of the exact position. The results clearly indicate that the ligand finds and discriminates the binding site with all other ligand positions on the surface involving significantly higher interaction energies (a second surface minimum at ~25–30 Å corresponds to a weak interaction with a second Mg$^{2+}$ ion present in the 221–226 loop). We should emphasize that the ligand is initially placed far from the active site (~30 Å) and is free to explore with no bias to the binding site. A supplemental movie illustrates some binding trajectories. Interestingly, we found the same number of trajectories where the ligand enters the binding site, interacting with the Mg$^{2+}$ ion, with either of the two phosphate atoms, P or P’. Moreover, the energies associated with these two different binding modes are similar.

To distinguish the possible preferred binding mode, we proceeded by running a ligand refinement search. This refinement step involves small ligand translations and large rotations within the active site, allowing it to reorient but not to move away. Fig. 1B shows the protein-ligand interaction energy against the P-Mg distance during the refinement exploration. For further insight into the preferred binding mode, the starting configuration for the 200 refinement trajectories had the same ligand orientation: P’ in contact (~4 Å) with the Mg$^{2+}$ ion; at this starting conformation, the P-Mg distance is ~10 Å. After a few PELE Monte Carlo steps, however, the distribution of P-Mg and P’-Mg binding modes reached ~50%. This is seen in Fig. 1B where two equally populated energy minima corresponding to both orientations (P-Mg values of ~4 and ~10 Å) are observed. The final model structures, which can be superposed with a protein all-heavy atom r.m.s.d. of 0.6 Å, are provided as supplemental Structures 2 (P-Mg) and 3 (P’-Mg).

PELE exploration is coupled with large backbone motion, allowing us to monitor closing or opening associated with the ligand dynamics. As mentioned, the initial model obtained from the 2AMY crystal represents an open state. Along with the binding process, however, we clearly observe the closing of both domains around the bound ligand; the supplemental movie clearly shows the closing process. A static view of domain closure is also shown in Fig. 2. The distance between Arg$^{21}$ and Glu$^{138}$ α-carbons experiences the largest change from 20 to 7.5 Å, moving from open to closed conformations, and the exposure of Arg$^{21}$ to solvent changes dramatically passing from 98% in 2AMY to 15% in the closed model. It was interesting to observe that this residue is preceded by a short stretch (18TAP20) in polyproline II conformation. Although this type of secondary structure is quite rare (28), in all structures solved by x-ray, a polyproline II stretch is observed in the same position. This is true not only for relatively close homologs (Protein Data Bank codes 2FUE, 2FUC, 2I54, and 2I55) but also in more distant ones (Protein Data Bank codes 3FRB and 4BND) (29).

Fig. 3 shows the protein-ligand interaction diagrams corresponding to the two binding modes. The orientations of the ligand in the two models are almost symmetrical and can be interconverted by rotation around an axis passing through O5.
(i.e. the oxygen in the ring) and C3 (i.e. the carbon opposite to it in the ring). As seen in Fig. 3, the interactions between the ligand and the protein are the same in the two orientations provided that we exchange the phosphate atoms. Residues lining the active site pocket can be precisely identified in the closed models, whereas they are ill-defined in 2AMY where domains are far apart. Although amino acid identity between PMM2 and PMM_LEIME is lower (54.8%) than between the two orthologous human enzymes (63.7%), the active site residues are more conserved with respect to PMM_LEIME (see Fig. 4). Active site residues mostly belong to the core domain (residues 1–81 and 189–247). The two domains come closer upon binding and are bridged by the bisphosphate sugar: one phosphate is bound to Lys189 of the core domain (Lys188 in PMM_LEIME), and the other phosphate is bound to Arg134 and Arg141 of the cap domain (Arg133 and Arg140 in PMM_LEIME). A high concentration of positively charged residues is observed in the contact area between domains where Arg21 and Arg141 (Arg19 and Arg140 in PMM_LEIME) should act like clasps as seen in Fig. 2.

Limited Proteolysis Reveals Conformational Changes Induced by Ligand Binding—Sugar bisphosphate binding makes the structure of PMM2 more compact. This effect was seen in silico (Fig. 2) and can be experimentally tested by limited proteolysis by incubating the enzyme with trypsin in the presence or absence of Glc-1,6-P2 and measuring residual phosphomannomutase activity (Fig. 5A). We observed that binding bisphosphate sugar completely protected the enzyme (Fig. 5A, trian-
Glc-1P had only a partial protective effect (Fig. 5B, open circles) that was potentiated by the addition of vanadate, a close structural and chemical mimic of phosphate (Fig. 5B, filled squares).

To further probe conformational changes in PMM2, we targeted the clasp between domains where the largest displacements are expected using a protease more selective than trypsin. Interestingly, Arg21 belongs to a stretch of amino acids, 11FDVDGTLTAPRQKITKEMDD30, where a Pro is found in position P2, a hydrophobic amino acid is found in position P3, nonacidic amino acids are found in positions P1/H11032 and P2/H11032, and Asp is found in position P10. This stretch represents the only thrombin cleavage site in PMM2. We carried out limited proteolysis on the wild type enzyme as well as on the R141H and F119L mutants, both of which are clinically relevant. Mutation (to His) of Arg141 in the active site (see Fig. 3) lowered activity to approximately one-hundredth of that of wild type (data not shown). Phe119, on the other side, shifts the dimeric population toward the monomer (11), facilitating the access to proteases. We reasoned that sensitivity to thrombin would be maximal for the monomeric mutant F119L, that Glc-1,6-P2 would induce domain closure and hence Arg 21 protection, and that its effect would be minimal on the inactive mutant R141H.

**FIGURE 4. PMM2, PMM1, and PMM_LEIME sequence alignment.** Sequence alignment of PMM2, PMM1, and PMM_LEIME is shown. Active site residues are highlighted. The alignment shows that active site residues are less conserved between the two paralogous human enzymes than between PMM2 and the protozoan enzyme ortholog.

**FIGURE 5. Limited proteolysis of wild type phosphomannomutase2 with trypsin monitored by assaying residual mutase activity.** Purified wild type phosphomannomutase2 (1.4 mg/ml in 20 mM Hepes, pH 7.5 containing 150 mM NaCl and 1 mM MgCl2) was incubated at 37 °C with (or without) trypsin (protease:enzyme ratio, 1:20) in the presence of 0.5 mM Glc-1,6-P2 (A) or 0.5 mM Glc-1-P, 0.5 mM vanadate, or 0.5 mM Glc-1-P plus 0.5 mM vanadate (B). Residual phosphomannomutase activity is reported as a percentage with activity at time 0 defined as 100%. The protective effect of ligands increases as negative charges are added.
PMM2 wild type or mutants were incubated for different times in the presence of thrombin with or without 0.5 mM Glc-1,6-P2. After inactivation of the protease, the residual mutase activity of wild type or F119L was assayed under standard conditions (R141H lacks activity). The results (Fig. 6) clearly show a decrease of activity with incubation time, indicating that Arg21 is accessible to the protease. Upon ligand binding, however, PMM2 becomes more resistant to thrombin, an effect significantly more strong in F119L. Kinetic data shown are representative of three independent experiments.

Time course samples at 0, 40, and 120 min were also analyzed by RP-LC-MS analysis (Fig. 7). As expected, all samples were hydrolyzed in two main fragments corresponding to peptides 2–21 (the initial Met is removed in mature PMM2) and 22–245, respectively, confirming that Arg21 is the primary thrombin cleavage site. In the absence of ligand, release of peptide 2–21 was faster for F119L, slower for R141H, and even slower for WT (Fig. 7, A, C, and E). Interestingly, the presence of ligand protected against proteolysis of not only the active proteins (Fig. 7, B and D) but also the R141H inactive mutant (Fig. 7F). Peaks in Fig. 7 are extracted from RP-LC-MS chromatograms at a value of m/z 993.0, corresponding to the doubly charged ions of a species at a monoisotopic mass of 1984.0 Da. This mass value is solely compatible with the fragment 2–21 in the protein sequence digested by trypsin-like proteases. To further confirm the identity of the peptide, the ion at m/z 993.0 was fragmented by gas collisions in an electrospray ionization-tandem mass spectrometry (MS-MS) experiment. Two major fragments compatible with the loss of Ala-Ala from the N terminus (doubly charged y ion at 922.53) and with the loss of Leu-Thr-Ala-Pro-Arg from the C terminus (doubly charged b ion at 715.47), were recorded (Fig. 8).

To further confirm the in silico conformational changes in the PMM2 active site, we used a specific reagent, 1,2-cyclohexanedione (DHCH), that preferentially modifies reactive arginines (30). This compound is able to reversibly modify the guanidine group, generating a N°,Nε-(1,2-dihydroxycyclohex-1,2-ylene)-l-arginine (DHCH-arginine) with a protein mass increase of 112 Da for each modified arginine. Purified proteins (1.5 μM) were incubated at 37 °C with DHCH with or without
0.5 mM Glc-1,6-P_2. Aliquots of incubation mixtures were analyzed by RP-LC-MS after 20, 80, 140, and 200 min of reaction, and mass spectra of each protein, modified or not by DHCH, were recorded (Fig. 9). As reported in A and B, WT-PMM2 and F119L were progressively modified with up to two DHCH molecules added after 200 min. Conversely, only one DHCH adduct was observed for R141H under the same experimental conditions, demonstrating that Arg141 is one of the targets for DHCH. The area of the peaks of deconvoluted spectra relative to the modified forms of WT-PMM2, F119L, and R141H with or without Glc-1,6-P_2 was measured at different incubation times. The kinetics of DHCH modification was largely reduced (Fig. 9C) in presence of the ligand, indicating that target arginines become protected upon binding. The identity of the modified residues, Arg^{141} and Arg^{134}, was confirmed by running MALDI spectra of tryptic digestions of DHCH-modified proteins with or without Glc-1,6-P_2 (Fig. 10, A and B). Both residues belong to the active site (Fig. 3).

The behavior of R141H was somewhat unexpected. To test its ability to bind Glc-1,6-P_2, we carried out thermal shift assay. This technique exploits the fact that ligand binding increases the melting temperature of a protein. R141H was indeed stabilized by Glc-1,6-P_2 (Fig. 11C) although to a lesser extent than WT (Fig. 11A) or F119L (Fig. 11B). We observed that Glc-1-P binding stabilizes WT and F119L. The effect of the monophosphate sugar was potentiated by the addition of vanadate, which in the case of WT reaches the effect of Glc-1,6-P_2. In contrast, R141H was not stabilized by the sugar monophosphate irrespective of the presence of vanadate.

**Melting Curves Are Representative of Two Independent Experiments**—Finally, we also tested for the importance of the Mg^{2+} ion. We observed that Mg^{2+} is critical for protein stability (and for activity; data not shown) because curves obtained in the presence of EDTA (Fig. 12, open circles) are shifted to lower temperatures compared with those obtained in the presence of the ion (Fig. 12, open triangles). Importantly, Mg^{2+} cannot be substituted by other divalent ions, but on the contrary, Ca^{2+} acts as an inhibitor (Fig. 12). These findings reinforce the idea that 2AMY, which lacks a proper description of the ion binding site and the bound Mg^{2+} ion, cannot represent the native-like structure for PMM2.

**DISCUSSION**

Patients suffering from PMM2_CDG have residual enzymatic activity, and their parents, who have only one mutated allele and 50% activity, are asymptomatic. Drugs such as phar-
macological chaperones and/or activators (31) providing an increase in activity would be beneficial for them. The scarcity of biochemical and structural data, however, slows down the search for drugs. Our hypothesis states that the current crystallographic structure of PMM2 cannot be used for rational drug discovery because domains are too far apart, and Mg$^{2+}$/H$^{1+}$ ions are missing. Extensive computational and experimental studies have confirmed this point. Using recently developed computational techniques modeling non-biased ligand migration, active site search, and binding, we observed spontaneous binding in the same region as observed in homologous enzymes (PMM_LEIME). The binding process was coupled with significant protein reorganization in which a closed structure that required large domain motion was adopted.

Parallel to the all-atom modeling, limited proteolysis with trypsin, site-directed proteolysis with thrombin, and selective chemical modification confirmed closing of the enzyme upon ligand binding. Activity assays and thermal shift assays (this study and Ref. 11) showed the necessity of adding Mg$^{2+}$ and thus the missing loop interacting with it) for enzyme function and stability. Thus, overall, the PMM2 crystal structure represents a very poor model for rational drug design even for current flexible (receptor) docking techniques.

Our study indicates that Glc-1,6-P$_2$ can bind in two different modes. Because of the large symmetry of this sugar ligand, we found two equivalent bound structures where the P or P’ phosphates bind to Mg$^{2+}$. The presence of these two phosphate groups together with their large negative charge is crucial for

FIGURE 10. Identification of reactive arginines in phosphomannomutase2 monitored by MALDI mass spectrometry. A shows the MALDI mass spectrum of WT-PMM2 incubated with 1,2-cyclohexanedione (molar excess of 100) for 140 min and digested by trypsin for 90 min. B shows the list of MH$^+$ values measured by MALDI MS and attributed to tryptic peptides. Values at 1987.01 and 2088.90 atomic mass units were compatible with peptides 135–149 and 124–141 alternatively modified by 1,2-cyclohexanedione at Arg$^{141}$ and Arg$^{134}$, respectively.

FIGURE 11. Thermal stability of wild type, F119L, or R141H phosphomannomutase2 monitored by thermal shift assay. The profiles (A, WT; B, F119L; C, R141H) were assessed by thermal shift assays. Proteins (0.275 mg/ml in 20 mM Heps, pH 7.5, 2 mM MgCl$_2$, 150 mM NaCl, 1 mM dithiothreitol, 2.4 $\times$ SYPRO Orange) were heated from 25 to 80 °C at 0.5 °C/min, and fluorescence was recorded (excitation, 490 nm; emission, 575 nm). The experiment was performed in the presence of no ligand (light blue), 5 mM EDTA (blue), 0.5 mM Glc-1-P (red), 0.5 mM Glc-1-P plus 0.5 mM vanadate (black), and 0.5 mM Glc-1,6-P$_2$ (green).
domain closure. Corroborating experimental evidence comes from limited proteolysis and thermal shift assays. In fact, the resistance of the protein is minimal with a monophosphate sugar; intermediate with a monophosphate sugar plus vanadate, an inhibitor that mimics phosphate and recreates a complex similar to sugar 1,6-bisphosphate in the active site; and maximal with bisphosphate sugar.

Our models offer insights about the enzyme mechanism and identify active site residues. This is important to address therapy because mutations affecting these residues cannot be rescued with pharmacological chaperones (32). In addition, it is also important for diagnoses. As already mentioned, most patients are compound heterozygotes carrying one mutation, R141H (6). For these patients, we expect a residual activity below 50% and above 0%. What can we expect for people carrying two missense mutations but not R141H? Most mutations, which are pathologial in association with R141H, might not be pathological by themselves (i.e. A/R141H and B/R141H are pathological, and A/B not). We made a survey of the data available in the literature excluding the case where a stop codon, a frameshift, or alternative splicing was observed. We found that approximately 40% of the patients who do not carry R141H have a mutation that affects the active site as defined in this study (Figs. 3 and 4). This effect was reported for K51R, R123G, R123Q, G175R, and G176V (5, 33–35). We can expect that a mutation affecting these residues reduces functionality to such an extent that when combined with a second hypomorphic mutation will result in less than 50% residual activity.

Summing up these observations, we put forward the hypothesis that the occurrence of one mutation in the active site represents a condition sufficient but not necessary for pathology. It is worth remembering that other mutations such as F119L and D65Y not occurring in the active site are deleterious enough to confer pathology in the absence of R141H.

In the course of the experiments designed to validate the models generated by PELE, we learned that the common mutant R141H, which is inactive, binds bisphosphate sugar and undergoes domain closure. As seen in Fig. 3, numerous positive residues interact with the outer phosphate (away from the Mg" + ion) and stabilize domain closure. Thus, the influence of this mutation on enzymatic activity does not seem to be related to sugar binding. Awareness of the functioning of R141H is important when studying heterodimers with active mutants because the vast majority of PMM2-CDG patients have this type of enzyme.

In summary, combining modern computational techniques capable of modeling non-biased ligand migration and protein dynamics with limited and site-directed proteolysis, we have produced the first accurate model of a ligand-bound complex for PMM2. Moreover, our studies provide valuable insight into the behavior of key mutants.

Acknowledgment—We are grateful to Emilio Castelluccio for technical assistance.

REFERENCES
1. Matthijs, G., Schollen, E., Heykants, L., and Grünewald, S. (1999) Phosphomannomutase deficiency: the molecular basis of the classical Jaeken syndrome (CDGS type Ia). Mol. Genet. Metab. 68, 220–226
2. Stenson, P. D., Mort, M., Ball, E. V., Shaw, K., Phillips, A., and Cooper, D. N. (2014) The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomics medicine. Hum. Genet. 133, 1–9
3. Schollen, E., Kjaergaard, S., Legius, E., Schwartz, M., and Matthijs, G. (2000) Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). Eur. J. Hum. Genet. 8, 367–371
4. Kjaergaard, S., Skovby, F., and Schwartz, M. (1998) Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. Eur. J. Hum. Genet. 6, 331–336
5. Bjursell, C., Wahlström, J., Berg, K., Stibler, H., Kristiansson, B., Matthijs, G., and Martinsson, T. (1998) Detailed mapping of the phosphomannomutase 2 (PMM2) gene and mutation detection enable improved analysis for Scandinavian CDG type I families. Eur. J. Hum. Genet. 6, 603–611
6. Grünewald, S. (2009) The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochem. Biophys. Acta 1792, 827–834
7. Cromphout, K., Vleugels, W., Heykants, L., Schollen, E., Keldermans, L., Sciøt, R., D’Hooge, R., De Deyn, P. P., von Figura, K., Hartmann, D., Körner, C., and Matthijs, G. (2006) The normal phenotype of Pmm1-deficient mice suggests that Pmm1 is not essential for normal mouse development. Mol. Cell. Biol. 26, 5621–5635
8. Pirard, M., Achouri, Y., Collet, J. F., Schollen, E., Matthijs, G., and Van Schaftingen, E. (1999) Kinetic properties and tissular distribution of mammalian phosphomannomutase isoforms. Biochem. J. 339, 201–207
9. Silvaggi, N. R., Zhang, C., Lu, Z., Dai, J., Dunaway-Mariano, D., and Allen, K. N. (2006) The x-ray crystal structures of human α-phosphomannomutase 1 reveal the structural basis of congenital disorder of glycosylation type 1a. J. Biol. Chem. 281, 14918–14926
10. Kedzierski, L., Malby, R. L., Smith, B. J., Perugini, M. A., Hodder, A. N., Ilg, T., Colman, P. M., and Handman, E. (2006) Structure of Leishmania mexicana phosphomannomutase highlights similarities with human isoforms. J. Mol. Biol. 363, 215–227
11. Andreotti, G., Pedone, E., Giordano, A., and Cubellis, M. V. (2013) Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation. Mol. Genet. Genomic Med. 1, 32–44
12. Schneider, A., Thiel, C., Rindermann, J., DeRossi, C., Popovici, D., Hoffmann, G. F., Grüne, H. J., and Körner, C. (2012) Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice. Nat. Med. 18, 71–73
13. Sharma, V., Ichikawa, M., He, P., Scott, D. A., Bravo, Y., Dahl, R., Ng, B. G.,
Modeling the Conformational Transition in PMM2

Cosford, N. D., and Freeze, H. H. (2011) Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts. J. Biol. Chem. 286, 39431–39438

14. Vega, A. I., Pérez-Cerdá, C., Desviat, L. R., Matthijs, G., Ugarte, M., and Pérez, B. (2009) Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type Ia. Hum. Mutat. 30, 795–803

15. Eklund, E. A., Merbouh, N., Ichikawa, M., Nishikawa, A., Clima, J. M., Dorman, J. A., Norberg, T., and Freeze, H. H. (2005) Hydrophobic Man-1-P derivatives correct abnormal glycosylation in type I congenital disorder of glycosylation fibroblasts. Glycobiology 15, 1084–1093

16. Shan, Y., Kim, E. T., Eastwood, M. P., Dror, R. O., Seeliger, M. A., and Shaw, D. E. (2011) How does a drug molecule find its target binding site? J. Am. Chem. Soc. 133, 9181–9183

17. Takahashi, R., Gil, V. A., and Guallar, V. (2014) Monte Carlo free ligand diffusion with Markov state model analysis and absolute binding free energy calculations. J. Chem. Theory Comput. 10, 282–288

18. Borrelli, K. W., Vitalis, A., Alcantara, R., and Guallar, V. (2005) PELE: protein energy landscape exploration. A novel Monte Carlo based technique. J. Chem. Theory Comput. 1, 1304–1311

19. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254

20. Schrödinger, LLC (2011) Protein Preparation Wizard, Epik version 2.2, Impact version 5.7, Prime version 3.0, Schrödinger, LLC, New York

21. Kaminski, G. A., and Friesner, R. A. (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J. Phys. Chem. B 105, 6474–6487

22. Onufriev, A., Bashford, D., and Case, D. A. (2004) Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins 55, 383–394

23. Mizuguchi, K., Deane, C. M., Blundell, T. L., Johnson, M. S., and Overington, J. P. (1998) JOY: protein sequence-structure representation and analysis. Bioinformatics 14, 617–623

24. Connolly, M. L. (1983) Solvent-accessible surfaces of proteins and nucleic acids. Science 221, 709–713

25. Cubells, M. V., Cailléz, F., and Lovell, S. C. (2005) Secondary structure assignment that accurately reflects physical and evolutionary characteristics. BMC Bioinformatics 6, Suppl. 4, S8

26. Cammisà, M., Correra, A., Andreotti, G., and Cubells, M. V. (2013) Identification and analysis of conserved pockets on protein surfaces. BMC Bioinformatics 14, Suppl. 7, S9

27. Petersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612

28. Cubells, M. V., Cailléz, F., Blundell, T. L., and Lovell, S. C. (2005) Properties of polyproline II, a secondary structure element implicated in protein-protein interactions. Proteins 58, 880–892

29. Nogly, P., Matias, P. M., de Rosa, M., Castro, R., Santos, H., Neves, A. R., and Archer, M. (2013) High-resolution structure of an atypical α-phosphoglucomutase related to eukaryotic phosphomannomutases. Acta Crystallogr. D Biol. Crystallogr. 69, 2008–2016

30. Patthy, L., and Smith, E. L. (1975) Identification of functional arginine residues in ribonuclease A and lysozyme. J. Biol. Chem. 250, 565–569

31. Leidenheimer, N. J., and Ryder, K. G. (2014) Pharmacological chaperoning: a primer on mechanism and pharmacology. Pharmacol. Res. 83, 10–19

32. Andreotti, G., Guarracino, M. R., Cammisà, M., Correra, A., and Cubells, M. V. (2010) Prediction of the responsiveness to pharmacological chaperones: lysosomal human α-galactosidase, a case of study. Orphanet. J. Rare Dis. 5, 36

33. Vermeer, S., Kremer, H. P., Leijten, Q. H., Scheffer, H., Matthijs, G., Wevers, R. A., Knoers, N. A., Morava, E., and Lefeber, D. J. (2007) Cerебellar ataxia and congenital disorder of glycosylation Ia (CDG-Ia) with normal routine CDG screening. J. Neurol. 254, 1356–1358

34. Briones, P., Vilaseca, M. A., Schollen, E., Ferrer, I., Maties, M., Busquets, C., Artuch, R., Gort, L., Marco, M., van Schaftingen, E., Matthijs, G., Jaeken, J., and Chabás, A. (2002) Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia. J. Inherit. Metab. Dis. 25, 635–646

35. Le Bizet, C., Vuillaume-Berrot, S., Barnier, A., Dupre, T., Durand, G., and Seta, N. (2005) A new insight into PMM2 mutations in the French population. Hum. Mutat. 25, 504–505